8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
May 7, 2026·SEC
BridgeBio Pharma, Inc.(BBIO)Earnings, Financials & Key Ratios
BBIO•NASDAQ
Price updated Jun 19, 2026
AboutBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Show more
- Revenue$502M+126.3%
- EBITDA-$560M+4.6%
- Net Income-$729M-36.1%
- EPS (Diluted)-3.79-31.6%
- Gross Margin94.37%-4.0%
- EBITDA Margin-111.55%+57.8%
- Operating Margin-113.35%+57.6%
- Net Margin-145.26%+39.8%
BBIO Key Insights
BridgeBio Pharma, Inc. (BBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 127.4%
✗Weaknesses
- ✗Profits declining 10.2% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BBIO Price & Volume
BridgeBio Pharma, Inc. (BBIO) stock price & volume — 10-year historical chart
Loading chart...
BBIO Growth Metrics
BridgeBio Pharma, Inc. (BBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years127.44%
3 Years86.3%
TTM355.17%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-6.23%
Return on Capital
10 Years-80.14%
5 Years-93.68%
3 Years-105.5%
Last Year-80.55%
BBIO Recent Earnings
BridgeBio Pharma, Inc. (BBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.84-23.8%
$0.68
Rev
$195M+9.2%
$178M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$1.00-40.2%
$0.71
Rev
$154M+5.0%
$147M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.95-8.0%
$0.88
Rev
$121M-18.5%
$148M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.95-14.5%
$0.83
Rev
$111M+2.3%
$108M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.84vs $0.68-23.8% | $195Mvs $178M+9.2% |
| Q1 2026 | Feb 24, 2026 | $1.00vs $0.71-40.2% | $154Mvs $147M+5.0% |
| Q4 2025 | Oct 29, 2025 | $0.95vs $0.88-8.0% | $121Mvs $148M-18.5% |
| Q3 2025 | Aug 5, 2025 | $0.95vs $0.83-14.5% | $111Mvs $108M+2.3% |
Based on last 12 quarters of dataView full earnings history →
BBIO Peer Comparison
BridgeBio Pharma, Inc. (BBIO) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARRY | 1.23B | 8.00 | -10.96 | 40.22% | -5.56% | -20.64% | 2.94 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare BBIO vs Peers
BridgeBio Pharma, Inc. (BBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBIO Income Statement
BridgeBio Pharma, Inc. (BBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 40.56M | 8.25M | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M | 579.96M |
Revenue Growth % | - | - | - | -79.66% | 745.14% | 11.38% | -88.02% | 2285.27% | 126.26% | 355.17% |
Cost of Goods Sold | 260K | 0 | 2.5M | 0 | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M | 36.06M |
COGS % of Revenue | - | - | 6.16% | - | 4.47% | 4.42% | 26.29% | 1.75% | 5.63% | - |
Gross Profit | -260K▲ 0% | 0▲ 100.0% | 38.06M▲ 0% | 8.25M▼ 78.3% | 66.6M▲ 707.4% | 74.21M▲ 11.4% | 6.86M▼ 90.8% | 218.02M▲ 3079.6% | 473.81M▲ 117.3% | 543.9M▲ 0% |
Gross Margin % | - | - | 93.84% | 100% | 95.53% | 95.58% | 73.71% | 98.25% | 94.37% | 93.78% |
Gross Profit Growth % | - | 100% | - | -78.33% | 707.39% | 11.43% | -90.76% | 3079.58% | 117.32% | - |
Operating Expenses | 43.86M | 183.66M | 304.3M | 482.73M | 643.23M | 586.42M | 614.23M | 811M | 1.04B | 1.11B |
OpEx % of Revenue | - | - | 750.25% | 5851.99% | 922.65% | 755.22% | 6602.46% | 365.48% | 207.72% | - |
Selling, General & Admin | 13.3M | 43.59M | 94.35M | 145.68M | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M | 612.67M |
SG&A % of Revenue | - | - | 232.63% | 1766.08% | 275.7% | 184.41% | 1618.73% | 130.21% | 110.57% | - |
Research & Development | 30.56M | 140.07M | 209.95M | 337.05M | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M | 492.74M |
R&D % of Revenue | - | - | 517.62% | 4085.91% | 646.94% | 514.45% | 4898.54% | 228.24% | 95.11% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 43.77M | 7.93M | 15.61M | 10.22M | 1.32M |
Operating Income | -43.86M▲ 0% | -183.66M▼ 318.8% | -266.24M▼ 45.0% | -474.48M▼ 78.2% | -576.63M▼ 21.5% | -512.2M▲ 11.2% | -607.37M▼ 18.6% | -592.97M▲ 2.4% | -569.09M▲ 4.0% | -570.67M▲ 0% |
Operating Margin % | - | - | -656.41% | -5751.99% | -827.12% | -659.65% | -6528.75% | -267.22% | -113.35% | -98.4% |
Operating Income Growth % | - | -318.76% | -44.96% | -78.22% | -21.53% | 11.17% | -18.58% | 2.37% | 4.03% | - |
EBITDA | -43.6M | -183.41M | -265.38M | -473.03M | -570.79M | -505.43M | -600.88M | -586.9M | -560.09M | -561.77M |
EBITDA Margin % | - | - | -654.29% | -5734.34% | -818.73% | -650.93% | -6458.95% | -264.49% | -111.55% | -96.86% |
EBITDA Growth % | - | -320.7% | -44.69% | -78.24% | -20.67% | 11.45% | -18.88% | 2.33% | 4.57% | 18.81% |
D&A (Non-Cash Add-back) | 260K | 245K | 859K | 1.46M | 5.84M | 6.77M | 6.49M | 6.08M | 9M | 8.9M |
EBIT | -43.82M | -183.66M | -279.82M | -468.83M | -539.68M | -404.21M | -571.96M | -442.9M | -681.88M | -609.96M |
Net Interest Income | 26K | -543K | 150K | -32.64M | -45.65M | -72.9M | -63.25M | -82.04M | -33.25M | -93.48M |
Interest Income | 39K | 2M | 8.91M | 4.01M | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M | 20.71M |
Interest Expense | 13K | 2.55M | 8.77M | 36.66M | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M | 114.19M |
Other Income/Expense | 26K | 14.21M | -22.34M | -31.01M | -9.82M | 27.55M | -45.88M | 50.78M | -165.9M | -161.26M |
Pretax Income | -43.83M▲ 0% | -169.45M▼ 286.6% | -288.58M▼ 70.3% | -505.49M▼ 75.2% | -586.45M▼ 16.0% | -484.65M▲ 17.4% | -653.25M▼ 34.8% | -542.19M▲ 17.0% | -734.99M▼ 35.6% | -731.93M▲ 0% |
Pretax Margin % | - | - | -711.5% | -6127.87% | -841.2% | -624.17% | -7021.94% | -244.34% | -146.39% | -126.2% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M | 555K | 555K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.21% | -0.08% | -0.08% |
Net Income | -30.57M▲ 0% | -130.75M▼ 327.8% | -260.44M▼ 99.2% | -448.72M▼ 72.3% | -562.54M▼ 25.4% | -481.18M▲ 14.5% | -643.2M▼ 33.7% | -535.76M▲ 16.7% | -729.31M▼ 36.1% | -725.93M▲ 0% |
Net Margin % | - | - | -642.1% | -5439.74% | -806.9% | -619.7% | -6913.92% | -241.44% | -145.26% | -125.17% |
Net Income Growth % | - | -327.77% | -99.19% | -72.3% | -25.36% | 14.46% | -33.67% | 16.7% | -36.13% | -8.68% |
Net Income (Continuing) | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -653.25M | -543.35M | -735.54M | -732.49M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 3.33M | 62.48M | 67.52M | 49.98M | 4.83M | 9.69M | 11.72M | 10.29M | -570K | -951K |
EPS (Diluted) | -0.33▲ 0% | -1.42▼ 330.3% | -2.48▼ 74.6% | -4.10▼ 65.3% | -3.90▲ 4.9% | -3.35▲ 14.1% | -3.95▼ 17.9% | -2.88▲ 27.1% | -3.79▼ 31.6% | -3.73▲ 0% |
EPS Growth % | - | -330.3% | -74.65% | -65.32% | 4.88% | 14.1% | -17.91% | 27.09% | -31.6% | -6.23% |
EPS (Basic) | -0.33 | -1.42 | -2.48 | -4.10 | -3.90 | -3.35 | -3.95 | -2.88 | -3.79 | - |
Diluted Shares Outstanding | 92.33M | 92.33M | 105.1M | 118M | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M | 194.79M |
Basic Shares Outstanding | 92.33M | 92.33M | 105.1M | 118M | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M | 194.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BBIO Balance Sheet
BridgeBio Pharma, Inc. (BBIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 97.13M | 445.22M | 568.62M | 642.82M | 888.86M | 548.85M | 477.59M | 720.69M | 753.68M | 1.18B |
Cash & Short-Term Investments | 92M | 436.09M | 545.99M | 607.09M | 836.66M | 471.92M | 434.88M | 681.1M | 587.48M | 940.19M |
Cash Only | 92M | 436.09M | 363.77M | 356.08M | 393.77M | 376.69M | 375.94M | 681.1M | 570.12M | 879.89M |
Short-Term Investments | 0 | 0 | 182.22M | 251.01M | 442.89M | 95.23M | 58.95M | 0 | 17.36M | 60.3M |
Accounts Receivable | 0 | 0 | 2.85M | 0 | 19.75M | 17.08M | 1.75M | 4.72M | 139.44M | 205.23M |
Days Sales Outstanding | - | - | 25.6 | - | 103.4 | 80.28 | 68.7 | 7.77 | 101.37 | 84.66 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.75M | 32.98M |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | 345.38 | 259.48 |
Other Current Assets | 889K | 0 | 0 | 139K | 177K | 37.93M | 27.65M | 3.83M | 0 | 0 |
Total Non-Current Assets | 913K | 19.72M | 63.06M | 60.76M | 123.93M | 74.18M | 68.79M | 198.65M | 41.59M | 49.53M |
Property, Plant & Equipment | 440K | 1.57M | 5.63M | 36.83M | 45.97M | 25.25M | 19.84M | 12.78M | 13.52M | 22.17M |
Fixed Asset Turnover | - | - | 7.21x | 0.22x | 1.52x | 3.08x | 0.47x | 17.37x | 37.15x | 38.43x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 44.93M | 28.71M | 26.32M | 23.93M | 28.08M | 27.36M |
Long-Term Investments | 381K | 17.05M | 31.14M | 0 | 0 | 0 | 0 | 143.75M | 81.44M | 346.42M |
Other Non-Current Assets | 92K | 1.09M | 26.29M | 23.93M | 33.03M | 20.22M | 22.63M | 18.2M | -81.44M | -63.11M |
Total Assets | 98.04M▲ 0% | 464.94M▲ 374.2% | 631.68M▲ 35.9% | 703.59M▲ 11.4% | 1.01B▲ 43.9% | 623.04M▼ 38.5% | 546.38M▼ 12.3% | 919.34M▲ 68.3% | 936.02M▲ 1.8% | 1.37B▲ 0% |
Asset Turnover | - | - | 0.06x | 0.01x | 0.07x | 0.12x | 0.02x | 0.24x | 0.54x | 0.53x |
Asset Growth % | - | 374.22% | 35.86% | 11.38% | 43.95% | -38.48% | -12.3% | 68.26% | 1.82% | 143.42% |
Total Current Liabilities | 8.55M | 32.58M | 60.38M | 95.65M | 135.07M | 121.43M | 143.84M | 154.4M | 287.97M | 816.37M |
Accounts Payable | 1.89M | 13.51M | 8.85M | 8.95M | 11.88M | 11.56M | 10.65M | 9.62M | 36.23M | 29.06M |
Days Payables Outstanding | 2.65K | - | 1.29K | - | 1.39K | 1.23K | 1.59K | 905.25 | 467.7 | 278.67 |
Short-Term Debt | 0 | 0 | 0 | 1.46M | 0 | 0 | 0 | 0 | 17.41M | 573.41M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 8.16M | 6.1M | 0 | 20.27M | 57.79M |
Other Current Liabilities | 997K | 4.01M | 25.39M | 9.55M | 37.04M | 31.26M | 65.59M | 16.2M | 214.06M | 196.01M |
Current Ratio | 11.36x | 13.67x | 9.42x | 6.72x | 6.58x | 4.52x | 3.32x | 4.67x | 2.62x | 1.44x |
Quick Ratio | 11.36x | 13.67x | 9.42x | 6.72x | 6.58x | 4.52x | 3.32x | 4.67x | 2.52x | 1.40x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -20.95 | 65.46 |
Total Non-Current Liabilities | 144.18M | 533.87M | 95.32M | 500.05M | 1.74B | 1.75B | 1.75B | 2.22B | 2.72B | 2.82B |
Long-Term Debt | 143.87M | 54.51M | 91.79M | 475.86M | 1.7B | 1.71B | 1.73B | 1.72B | 2.71B | 2.8B |
Capital Lease Obligations | 0 | 0 | 0 | 14.68M | 17.43M | 12.27M | 8.98M | 4.7M | 3.81M | 25.48M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 312K | 479.36M | 3.53M | 9.52M | 22.07M | 26.64M | 9.36M | 496.47M | 244K | 229K |
Total Liabilities | 152.73M | 566.44M | 155.7M | 595.7M | 1.88B | 1.87B | 1.89B | 2.38B | 3.01B | 3.64B |
Total Debt | 143.87M | 54.51M | 91.79M | 495.79M | 1.73B | 1.72B | 1.74B | 1.73B | 2.73B | 3.38B |
Net Debt | 51.87M | -381.58M | -271.98M | 139.71M | 1.33B | 1.35B | 1.36B | 1.05B | 2.16B | 2.5B |
Debt / Equity | - | - | 0.19x | 4.60x | - | - | - | - | - | -1.49x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -6.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.46x |
Interest Coverage | -3370.69x | -72.11x | -31.92x | -12.79x | -11.54x | -5.03x | -7.04x | -4.46x | -12.84x | -5.34x |
Total Equity | -54.69M▲ 0% | -101.5M▼ 85.6% | 475.98M▲ 568.9% | 107.89M▼ 77.3% | -865.58M▼ 902.3% | -1.24B▼ 43.8% | -1.34B▼ 7.8% | -1.46B▼ 8.6% | -2.08B▼ 42.5% | -2.27B▲ 0% |
Equity Growth % | - | -85.61% | 568.93% | -77.33% | -902.31% | -43.83% | -7.84% | -8.57% | -42.5% | -203.18% |
Book Value per Share | -0.59 | -1.10 | 4.53 | 0.91 | -6.00 | -8.44 | -8.25 | -7.83 | -10.53 | -11.65 |
Total Shareholders' Equity | -58.02M | -163.99M | 408.45M | 57.91M | -870.41M | -1.25B | -1.35B | -1.47B | -2.08B | -2.27B |
Common Stock | 3.41M | 6.59M | 124K | 125K | 154K | 157K | 181K | 196K | 202K | 204K |
Retained Earnings | -61.43M | -170.58M | -440.03M | -888.75M | -1.44B | -1.92B | -2.56B | -3.1B | -3.82B | -3.99B |
Treasury Stock | 0 | 0 | 0 | -75M | -275M | -275M | -275M | -275M | -323.28M | -405.78M |
Accumulated OCI | -27K | -231K | 254K | 192K | -132K | -328K | 31K | 8K | 12K | -8K |
Minority Interest | 3.33M | 62.48M | 67.52M | 49.98M | 4.83M | 9.69M | 11.72M | 10.29M | -570K | -951K |
BBIO Cash Flow Statement
BridgeBio Pharma, Inc. (BBIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -40.49M | -136.64M | -253.59M | -399.71M | -497.93M | -419.49M | -527.72M | -520.73M | -445.91M | -443.95M |
Operating CF Margin % | - | - | -625.21% | -4845.61% | -714.23% | -540.25% | -5672.58% | -234.66% | -88.81% | - |
Operating CF Growth % | - | -237.49% | -85.58% | -57.62% | -24.57% | 15.75% | -25.8% | 1.33% | 14.37% | -96.59% |
Net Income | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -643.2M | -543.35M | -724.93M | -725.93M |
Depreciation & Amortization | 260K | 245K | 859K | 3.09M | 5.84M | 6.77M | 6.49M | 6.08M | 5.97M | 5.99M |
Stock-Based Compensation | 1.84M | 6.07M | 21.37M | 58.46M | 99.5M | 91.56M | 0 | 95.8M | 133.02M | 105.12M |
Deferred Taxes | -260K | -14.89M | -859K | -1.87M | -30.93M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 260K | 18.89M | 24.54M | 31.16M | 18.5M | -61.25M | 103.93M | -111.3M | 191.09M | 227.9M |
Working Capital Changes | 1.24M | 22.49M | -10.91M | 14.93M | -4.4M | 28.08M | 5.06M | 32.04M | -51.06M | -59.64M |
Change in Receivables | 0 | 0 | -2.85M | 2.85M | -19.75M | 15.17M | 15.33M | -2.97M | -134.72M | -89.96M |
Change in Inventory | 0 | 0 | 2.85M | -2.85M | 19.75M | 0 | 0 | 0 | -25.31M | -29.17M |
Change in Payables | 1.58M | 16.7M | -4.66M | -735K | 2.83M | -349K | 2.78M | 1.51M | 26.61M | 1.87M |
Cash from Investing | -464K | -21.04M | -217.25M | -52.99M | -200.83M | 453.15M | 54.03M | 60.78M | -24.49M | -65.03M |
Capital Expenditures | -464K | -18.18M | -5.14M | -7.52M | -48.25M | -4.82M | -1.31M | -933K | -1.1M | -3.57M |
CapEx % of Revenue | - | - | 12.67% | 91.14% | 69.2% | 6.21% | 14.04% | 0.42% | 0.22% | 0.61% |
Acquisitions | 2.84M | -2.86M | -5.49M | 21.24M | -35M | 0 | 0 | -140K | 0 | 600K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -2.86M | 784K | -21.09M | 48.65M | 118.5M | -503K | -7.97M | -6.19M | -2.2M |
Cash from Financing | 112.98M | 501.55M | 398.79M | 447.19M | 736.45M | -13.13M | 451.54M | 748.46M | 359.29M | 848.26M |
Debt Issued (Net) | 4.13M | 56.38M | 36.94M | 550M | 1.08B | -20.49M | 0 | 476.58M | 385.5M | 893.96M |
Equity Issued (Net) | 107.02M | 430.53M | 366.24M | -75.71M | -204.75M | 3.29M | 442.93M | 307.21M | -14.13M | -35.21M |
Dividends Paid | -1.15M | 0 | -997K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -75.71M | -204.75M | -1.56M | -6.88M | -7.53M | -48.28M | -84.5M |
Other Financing | 1.83M | 14.64M | -4.38M | -27.1M | -138.49M | 4.06M | 8.61M | -35.34M | -12.08M | -10.49M |
Net Change in Cash | 72.03M▲ 0% | 343.87M▲ 377.4% | -72.05M▼ 121.0% | -5.52M▲ 92.3% | 37.69M▲ 783.0% | 20.52M▼ 45.6% | -22.15M▼ 208.0% | 288.51M▲ 1402.4% | -111.1M▼ 138.5% | 339.5M▲ 0% |
Free Cash Flow | -40.95M▲ 0% | -154.82M▼ 278.1% | -258.73M▼ 67.1% | -407.23M▼ 57.4% | -546.18M▼ 34.1% | -425.81M▲ 22.0% | -529.03M▼ 24.2% | -521.66M▲ 1.4% | -447.01M▲ 14.3% | -454.12M▲ 0% |
FCF Margin % | - | - | -637.88% | -4936.74% | -783.44% | -548.39% | -5686.62% | -235.09% | -89.03% | -78.3% |
FCF Growth % | - | -278.05% | -67.11% | -57.4% | -34.12% | 22.04% | -24.24% | 1.39% | 14.31% | 10.86% |
FCF per Share | -0.44 | -1.68 | -2.46 | -3.45 | -3.78 | -2.89 | -3.25 | -2.80 | -2.27 | -2.33 |
FCF Conversion (FCF/Net Income) | 1.32x | 1.05x | 0.97x | 0.89x | 0.89x | 0.87x | 0.82x | 0.97x | 0.61x | 0.63x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 54.44M | 61.11M | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BBIO Key Ratios
BridgeBio Pharma, Inc. (BBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -139.1% | -153.71% | - | - | - | - | - | 36.08% |
Return on Invested Capital (ROIC) | - | - | -157.61% | -121.07% | -135.08% | -738.78% | - | -524% | 713.34% |
Gross Margin | - | 93.84% | 100% | 95.53% | 95.58% | 73.71% | 98.25% | 94.37% | 93.78% |
Net Margin | - | -642.1% | -5439.74% | -806.9% | -619.7% | -6913.92% | -241.44% | -145.26% | -125.17% |
Debt / Equity | - | 0.19x | 4.60x | - | - | - | - | - | -1.49x |
Interest Coverage | -72.11x | -31.92x | -12.79x | -11.54x | -5.03x | -7.04x | -4.46x | -12.84x | -5.34x |
FCF Conversion | 1.05x | 0.97x | 0.89x | 0.89x | 0.87x | 0.82x | 0.97x | 0.61x | 0.63x |
Revenue Growth | - | - | -79.66% | 745.14% | 11.38% | -88.02% | 2285.27% | 126.26% | 355.17% |
Related:BBIO Dividend History·BBIO Revenue History·BBIO Price History·BBIO P/E History·BBIO Financial Ratios·BBIO Institutional Holders
BBIO SEC Filings & Documents
BridgeBio Pharma, Inc. (BBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
BBIO Frequently Asked Questions
BridgeBio Pharma, Inc. (BBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BridgeBio Pharma, Inc. (BBIO) reported $580.0M in revenue for fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) grew revenue by 126.3% over the past year. This is strong growth.
BridgeBio Pharma, Inc. (BBIO) reported a net loss of $725.9M for fiscal year 2025.
Dividend & Returns
BridgeBio Pharma, Inc. (BBIO) had negative free cash flow of $454.1M in fiscal year 2025, likely due to heavy capital investments.